Intrexon | XON - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Agenus USD 16.02M 2.85M 2025-12
Alaunos Therapeutics USD 1.07M 215K 2023-06
Amgen USD 653M 32M 2025-12
Anika Therapeutics 189.44M 1.76M 2025-09
Arrowhead Research USD 22.5M 811K 2025-12
AstraZeneca USD 484M 181M 2025-12
Bristol-Myers Squibb USD 432M 48M 2025-12
Gilead Sciences USD 255M 1000K 2025-12
GlaxoSmithKline GBP 188M 21M 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Incyte USD 582K 10K 2025-12
Intrexon USD 2K 5K 2024-06
Karyopharm Therapeutics USD 11.38M 2.43M 2024-09
Ligand Pharmaceuticals USD 910K 243K 2025-09
MacroGenics USD 3.34M 2.54M 2025-09
MannKind USD 13.87M 6.54M 2025-12
Merck USD 412M 85M 2025-12
Novartis USD 304M 23M 2025-12
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Thermo Fisher Scientific USD 365M 18M 2025-12
Veracyte USD 2K 1000 2023-12
Xencor USD 7.35M 311K 2025-12